Drugs That Act on the Immune System

This chapter serves as a review of publications in 2015 as they pertain to adverse drug events associated with cytokines and monoclonal antibodies. Large studies as well as case reports detailing previously unknown adverse effects are summarized for bone morphogenetic proteins, colony-stimulating factors, thrombopoietin agonists, interferons, interleukins, tumor necrosis factor alfa antagonists and many monoclonal antibodies. New monoclonal antibodies included in this edition are catumaxomab, daratumumab, dinutuximab, elotuzumab, evolocumab, idarucizumab, mepolizumab, necitumumab, nivolumab, ramucirumab and secukinumab.